Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wanner

Showing results (41-50 of 206) with videos related to

Pageof 21
Sort By:
Medizinische Klinik (Munich, Germany : 1983)|October 15, 1996
[Combination antihypertensive therapy in patients with an increased risk profile]W Bartens, M Nauck, C Wanner
Kidney International. Supplement|December 1, 1995
Clinical utility of antilipidemic therapies in chronic renal allograft failureC Wanner, W Bartens, J Galle
Immunitat Und Infektion|April 1, 1995
[Atherogenic lipoprotein(a) as a progression factor in glomerular diseases: studies in cultured rat mesangial cells]S Greiber, M Gutenkunst, C Wanner
Clinical Genetics|March 10, 2018
The D313Y genotype-Pathogenic mutation or polymorphism?D Oder, C Wanner, P Nordbeck
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology|May 22, 2008
Nomen est omen. Fabry diseaseF Weidemann, C Wanner, F Breunig
The Journal of Laboratory and Clinical Medicine|September 1, 1986
Urinary proteinase activity in patients with multiple traumatic injuries, sepsis, or acute renal failureC Wanner, P Schollmeyer, W H Hörl
Metabolism: Clinical and Experimental|March 1, 1988
Serum carnitine levels and carnitine esters of patients after kidney transplantation: role of immunosuppressionC Wanner, P Schollmeyer, W H Hörl
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 21, 2007
Use of HMG-CoA Reductase Inhibitors after Kidney and Heart Transplantation: Lipid-Lowering and Immunosuppressive EffectsC Wanner, A Krämer-Guth, J Galle
Clinical Nephrology|April 1, 1990
Control of hyperkalemia with fludrocortisone in a patient with systemic lupus erythematosusK W Dreyling, C Wanner, P Schollmeyer
Metabolism: Clinical and Experimental|July 1, 1997
Corticotropin increases the receptor-specific uptake of native low-density lipoprotein (LDL)--but not of oxidized LDL and native or oxidized lipoprotein(a) [Lp(a)]--in HEPG2 cells: no evidence for Lp(a) catabolism via the LDL-receptorW Bartens, A Krämer-Guth, C Wanner
Pageof 21

Showing results (41-50 of 206) with videos related to

Sort By:
Pageof 21
Medizinische Klinik (Munich, Germany : 1983)|October 15, 1996
[Combination antihypertensive therapy in patients with an increased risk profile]W Bartens, M Nauck, C Wanner
Kidney International. Supplement|December 1, 1995
Clinical utility of antilipidemic therapies in chronic renal allograft failureC Wanner, W Bartens, J Galle
Immunitat Und Infektion|April 1, 1995
[Atherogenic lipoprotein(a) as a progression factor in glomerular diseases: studies in cultured rat mesangial cells]S Greiber, M Gutenkunst, C Wanner
Clinical Genetics|March 10, 2018
The D313Y genotype-Pathogenic mutation or polymorphism?D Oder, C Wanner, P Nordbeck
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology|May 22, 2008
Nomen est omen. Fabry diseaseF Weidemann, C Wanner, F Breunig
The Journal of Laboratory and Clinical Medicine|September 1, 1986
Urinary proteinase activity in patients with multiple traumatic injuries, sepsis, or acute renal failureC Wanner, P Schollmeyer, W H Hörl
Metabolism: Clinical and Experimental|March 1, 1988
Serum carnitine levels and carnitine esters of patients after kidney transplantation: role of immunosuppressionC Wanner, P Schollmeyer, W H Hörl
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 21, 2007
Use of HMG-CoA Reductase Inhibitors after Kidney and Heart Transplantation: Lipid-Lowering and Immunosuppressive EffectsC Wanner, A Krämer-Guth, J Galle
Clinical Nephrology|April 1, 1990
Control of hyperkalemia with fludrocortisone in a patient with systemic lupus erythematosusK W Dreyling, C Wanner, P Schollmeyer
Metabolism: Clinical and Experimental|July 1, 1997
Corticotropin increases the receptor-specific uptake of native low-density lipoprotein (LDL)--but not of oxidized LDL and native or oxidized lipoprotein(a) [Lp(a)]--in HEPG2 cells: no evidence for Lp(a) catabolism via the LDL-receptorW Bartens, A Krämer-Guth, C Wanner
Pageof 21